期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 97, 期 2, 页码 726-745出版社
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.21024
关键词
DNA/oligonucleotide delivery; nonviral gene delivery; targeted drug delivery; biomaterials; nanotechnology
Successful gene therapy depends on the development of efficient delivery systems. Although pDNA and ODN are novel candidates for nonviral gene therapy, their clinical applications are generally limited owing to their rapid degradation by nucleases in serum and rapid clearance. A great deal of effort had been devoted to developing gene delivery systems, including physical methods and carrier-mediated methods. Both methods could improve transfection efficacy and achieve high gene expression in vitro and in vivo. As for carrier-mediated delivery in vivo, since gene expression depends on the particle size, charge ratio, and interaction with blood components, these factors must be optimized. Furthermore, a lack of cell-selectivity limits the wide application to gene therapy; therefore, the use of ligand-modified carriers is a promising strategy to achieve well-controlled gene expression in target cells. In this review, we will focus on the in vivo targeted delivery of pDNA and ODN using nonviral carriers. (C) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据